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Hepatopulmonary syndrome is an uncommon complication of nonacute liver failure, and in rare cases, hypoxia may be the
presenting sign of liver dysfunction. The condition, once thought to be a contraindication, is improved in most cases by
transplantation. There is a significant risk of postoperative, hypoxia-related morbidity and mortality in patients with
hepatopulmonary syndrome. We present a case of life-threatening hypoxia following liver transplantation for liver failure and
associated hepatopulmonary syndrome, with successful management using extracorporeal membrane oxygenation. Liver
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End-stage liver disease may present with multiple organ
dysfunction, which complicates the care of these critically
ill patients. Pulmonary manifestations of end-stage liver
disease include hepatopulmonary syndrome (HPS), which
occurs infrequently and with variable incidence. Clini-
cally, it is manifested by hypoxemia, elevated alveolar-
arterial gradient, dyspnea, and platypnea in association
with liver dysfunction. The diagnosis of HPS requires 3
elements: liver disease, hypoxemia, and intrapulmonary
vascular dilation. The wide variation in reported inci-
dences of HPS is due to the definition of hypoxemia used
in the determination.1,2 Some have defined hypoxia using
partial pressure of oxygen (PaO2) while the patient is
breathing room air,3 whereas other investigators have
used alveolar-arterial gradients in the definition.1,4 The
published incidence of HPS ranges from 4% to 32%.1,4-11
Hypoxemia has been correlated to risk of mortality for
these patients, and this suggests that an arterial PaO2 
50 mmHg at rest while the patient is breathing room air
carries the greatest risk for complications after orthotopic
liver transplantation (OLT).12-14 Although hypoxemia was
once a contraindication, liver transplantation appears to
reverse hypoxemia in 70% of patients and is more effec-
tive than current medical therapies.13,15 We present a
case of a child with HPS and profound hypoxemia post
liver transplantation who was successfully supported
with venovenous (V-V) extracorporeal membrane oxygen-
ation (ECMO) until his oxygenation improved enough to
allow for standard mechanical ventilation.
CASE PRESENTATION
A previously healthy 12-year-old, 40-kg male presented
with shortness of breath and fatigue. He was found to
have cirrhosis secondary to autoimmune hepatitis.
Liver function tests showed aspartate aminotransferase
of 304 IU/L, alanine aminotransferase of 219 IU/L,
total bilirubin of 1.4 mg/dL, international normaliza-
tion ratio of 1.5, serum albumin of 2.2 g/dL, and serum
creatinine without dialysis of 0.4 mg/dL; this gave him
a lab Model for End-Stage Liver Disease score of 14.
At presentation, he was hypoxemic with arterial oxy-
gen saturation (SaO2) of 86% while breathing room air,
with platypnea, orthodeoxia, and digital clubbing on
physical examination. Chest radiograph demonstrated
diffuse reticular markings at the lung field periphery,
without consolidation. Agitated saline contrast echo-
cardiography revealed a right-to-left extracardiac
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shunt, although computed tomography of the chest did
not demonstrate discrete arteriovenous malformations.
A ventilation-perfusion scan with technetium-99-m–la-
beled macroaggregated albumin scintigraphy revealed
normal ventilation with marked uptake in the brain,
thyroid, spleen, and kidneys, confirming the right-to-
left shunt physiology. Pulmonary function testing
showed normal spirometric values for his age with di-
minished carbon monoxide diffusion at 37% of the pre-
dicted value. An initial arterial blood gas demonstrated
a pH of 7.42, partial pressure of carbon dioxide of 35
mmHg, and PaO2 of 53 mmHg while he was breathing
room air.
In the weeks following initial presentation, his clinical
status deteriorated with worsening hypoxemia, which
rendered him bed-bound. His SaO2 ranged from 88% to
92% while he was breathing 6 liters per minute (Lpm)
oxygen via a face mask, and he had significant desatu-
rations with minimal activity. Hence, the United Net-
work for Organ Sharing regional review board was pe-
titioned, and he was listed for transplantation with an
exception Model for End-Stage Liver Disease score of
22, including a diagnosis of HPS. Two months after
presentation, he underwent uncomplicated deceased
donor OLT. The procedure was performed piggyback
without V-V bypass. He required 3 units of packed red
blood cells, 7 units of fresh frozen plasma, 275 mL of
cell saver fluid, and 2 L of crystalloid. On postoperative
day 1, the patient had good liver function and no re-
quirement of blood products.
On postoperative day 2, the patient’s trachea was
extubated, having met standard local intensive care
unit criteria of 4-6 mL/kg tidal breaths on continuous
positive airway pressure without significant tachypnea
or signs of respiratory distress. However, within 12
hours, because of persistently low SaO2 [75%-85% with
PaO2 of 36 mmHg on a fraction of inspired oxygen (FIO2)
of 0.8] and respiratory distress, he required urgent re-
intubation of the trachea and mechanical ventilatory
support. His settings on positive pressure ventilation
were 10 mL/kg tidal volume (reaching peak inspiratory
pressures of 28-30 cmH2O), positive end expiratory
pressure of 5 cmH2O, and mean airway pressure of
9-11 cmH2O. This resulted in SaO2 of 90%-95% on an
FIO2 of 0.8. Over the ensuing 3 days, his FIO2 and
ventilator settings were weaned, and on postoperative
day 5, his trachea was again extubated. He was transi-
tioned to a high-flow nasal cannula oxygen delivery
device (Vapotherm, Stevensville, MD) at 40 Lpm, and
his SaO2 was maintained at 90% on an FIO2 of 0.9-1;
however, further decompensation with respiratory dis-
tress and hypoxia required him to be transitioned to
noninvasive bilevel positive pressure ventilation of
18/8 cmH2O with FIO2 of 0.9. On postoperative day 6,
the patient developed fever and tachycardia without
leukocytosis, and blood cultures subsequently grew co-
agulase-negative staphylococcus from a central venous
catheter. The central venous catheter was removed,
and appropriate broad-spectrum antimicrobial therapy
was initiated. Previous and subsequent endotracheal
cultures were negative during his course. On postoper-
ative day 8, he had an acute decompensation with SaO2
below 60% and severe respiratory distress. He under-
went emergent endotracheal intubation and mechani-
cal ventilatory support. Attempts at lung recruitment
with positive pressure ventilation and FIO2 of 1.0 did
not improve his SaO2, and his chest radiograph at that
juncture showed increased parenchymal opacification
(Fig. 1). His total pulmonary compliance had decreased,
reaching peak inspiratory pressures of 35 cmH2O on
8-10 mL/kg tidal volumes. Nitric oxide at 40 parts per
million was added to his regimen without improvement
in oxygenation, PaO2 remaining at 31 mmHg. Because
of the failure of conventional ventilatory support, and in
the face of satisfactory graft function, he was consid-
ered to be a candidate for V-V ECMO.
Because currently available double lumen cannula
sizes are restricted to 18 French and smaller, a 23-
French venous drainage cannula was percutaneously
placed in the right internal jugular vein, and a 21-
French venous return cannula was similarly placed in
the right femoral vein. He remained on V-V ECMO for
18 days, during which time he was placed in the prone
position for periods ranging from 6 to 12 hours to opti-
Figure 1. Anterior-posterior
chest radiographs from postoper-
ative day 1 (left) and postopera-
tive day 8 (right) demonstrating a
marked increase in bilateral pul-
monary infiltrates.
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mize lung recruitment. His initial ECMO blood flow
rates were 3-3.6 Lpm, and they were slowly decreased
to 2 Lpm on ECMO days 12-13. After his ECMO blood
flow rate was decreased, his sweep gas FIO2 was slowly
weaned from 1.0 to 0.4. As he recovered from his cath-
eter-associated bloodstream infection and his ECMO
support was decreased, his SaO2 remained stable, with
a peak SaO2  central venous oxygen saturation differ-
ence of 26% and a lowest SaO2 recording of 79%. His
liver function remained stable, and liver enzymes con-
tinued to normalize; this suggested no adverse effects of
his graft during this weaning period (Fig. 2). Our insti-
tution practice is to maintain platelet counts  1  105
during ECMO support, and total platelet count data are
presented for his entire intensive care unit stay (Fig. 3).
Total blood product use for the ECMO course was 1188
mL of platelets and 4550 mL of packed red blood cells,
and no cryoprecipitate or fresh frozen plasma was ad-
ministered. On postoperative day 26 and ECMO day 18,
his ECMO cannulae were removed. Five days after sep-
aration from V-V ECMO, his trachea was extubated,
and he was transitioned to 2 Lpm oxygen by nasal
cannula with a PaO2 of 52 mmHg and SaO2 of 90%. By
postoperative day 51, his SaO2 was 99% with no sup-
plemental oxygen support. He was subsequently dis-
charged and is currently doing well greater than 1 year
post transplantation.
DISCUSSION
For many years, severe HPS was a contraindication to
liver transplantation. More recently, however, case re-
ports and series have demonstrated a reversal of this
process with liver transplantation.2 Worsening of hy-
poxemia may occur and contribute to posttransplanta-
tion mortality; however, if the posttransplant period is
survived, the outcome is generally favorable with rever-
sal of hypoxemia.12-13,15-17 The degree of pre-OLT hyp-
oxia associated with HPS has been felt to further delin-
eate patients at greatest risk for postoperative
complications and reduced survival; in one study, a
PaO2  60 mmHg was associated with an increased
mortality,11 whereas a subsequent study reports a
threshold for survival with a PaO2  50 mmHg.
14 Re-
gardless, significant hypoxia associated with HPS ap-
pears to portend an increased risk for complications
and mortality after OLT.
Although management of severe hypoxia related to
acute respiratory distress syndrome (ARDS) in neonatal
and pediatric patients using ECMO is not a novel con-
cept, its use after OLT for pulmonary complications is
infrequently reported, with no reference to patients
with HPS among these cases. Jeng et al.18 reported
ECMO support for hypoxia-mediated ARDS that devel-
oped after OLT for end-stage liver disease secondary to
hemochromatosis and hepatitis B infection. This 37-
year-old female was placed on ECMO (no indication of
mode) on postoperative day 18 and survived for 10 days
until the development of severe intracranial hemor-
rhage necessitating withdrawal of care. Szocik et al.19
reported ECMO support for a massive pulmonary em-
bolism that developed intraoperatively in a 54-year-old
female with biliary cirrhosis undergoing OLT. She was
supported with ECMO (no indication of mode) intraop-
eratively and weaned from support in the operative
suite. She died 9 weeks after OLT secondary to multi-
organ failure mediated by venacaval thrombosis. Fujita
et al.20 reported V-V ECMO support in a 1-month-old
female who developed pulmonary hemorrhage on post-
operative day 27 after OLT for idiopathic neonatal hep-
atitis. She was supported for a total of 4 days without
complication with repeat OLT performed on ECMO on
Figure 2. Liver aminotransferase levels during the post-OLT
period. Aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) are presented on the y axis in international
units per liter for each post-OLT day (x axis). The period of
ECMO is delineated with arrows in the graph with the appro-
priate legend. Additionally, the period of weaning of ECMO
support is delineated with arrows in the graph with the appro-
priate legend.
Figure 3. The platelet count in thousands (y axis) is pre-
sented during the post-OLT period (x axis). The period of
ECMO is delineated with arrows in the graph with the appro-
priate legend. Platelet transfusion is indicated by a circle
around data points on ECMO days 1 and 2.
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day 2 of support. She was weaned from ECMO and
survived to hospital discharge. Additional reference to
ECMO support post liver transplantation was noted
within a series documenting pediatric pulmonary com-
plications after OLT.21 Three patients ranging from 4 to
9 months of age were supported with ECMO after OLT
for respiratory tract infections with respiratory syncy-
tial virus, parainfluenza virus, and pseudomonas. Two
of the 3 patients were reported to survive to hospital
discharge.
The use of ECMO to support patients in the post-
transplantation period needs to be weighed against the
3 main risks: anticoagulation, cannula placement, and
infection. Although systemic anticoagulation is re-
quired during ECMO, the bleeding complications are
usually manageable even in patients in the postopera-
tive period. A growing population supported on ECMO
in this modern era is neonates requiring support after
congenital cardiac surgery correction.22 Although
bleeding is not uncommon in this group, it is success-
fully managed by minimization of heparin infusion
rates to target activated clotting times in the lowest
tolerable range. Cannula placement also requires con-
sideration after OLT, especially in the pediatric popula-
tion. Current ECMO coaxial or double lumen catheter
sizes are restricted to 18 French and smaller, necessi-
tating bicaval cannulation in patients greater than 15
kg for V-V support. Hence, the transplant surgeon will
consider the risk of femoral cannulation and proximity
to graft anastomosis against the risk for carotid artery
sacrifice necessary for venoarterial cannulation. Fi-
nally, infectious complications with ECMO are mini-
mized by aseptic technique and nursing care but re-
main a concern for any patient on ECMO.
Immunosuppression associated with solid organ trans-
plant does not appear to be a contraindication to ECMO
as experience grows with supporting posttransplanta-
tion organ failure.23,24
We present a case report of extracorporeal life sup-
port for life-threatening hypoxia complicating HPS after
OLT in a pediatric patient. The likely etiology of his
respiratory decompensation was exacerbation of severe
HPS by sepsis (as outlined by the International Pediat-
ric Sepsis Consensus Conference) -induced ARDS.25
Elimination of the source of bacteremia by removal of
the colonized central venous catheter, implementing
broad-spectrum antibiotic therapy, and allowing lung
parenchymal normalization are what ultimately re-
versed his condition. However, the severity of his respi-
ratory failure and decompensation required more sup-
port than conventional ventilatory strategies could
provide. Using V-V ECMO to provide this support while
ARDS and bacteremia could be treated was successful,
as it gave the management team the ability to carry out
effective lung recruitment and pulmonary toileting
strategies during the period of improvement in in-
trapulmonary shunting.
Because of the marked advances in conventional ven-
tilatory management, fewer patients are supported with
ECMO for traditional respiratory failure. However, this
does not make ECMO obsolete, as it clearly still has a
role in complex, physiologically challenging patients. In
this case, ECMO provided a safe and viable option for
severe hypoxemic respiratory failure in conjunction
with HPS in the post–liver transplantation period.
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